Tetsutaro Hayashi

<i>Kdm6a</i> Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with <i>p53</i> Dysfunction

Kohei Kobatake, Kenichiro Ikeda, Yuichiro Nakata et al. · Clinical Cancer Research · 2020 · 171 citations

Medicine, Molecular Biology, Oncology +15

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy

Bernhard Kiss, Alexander W. Wyatt, James J. Douglas et al. · Scientific Reports · 2017 · 115 citations · Full text

Medicine, Molecular Biology, Oncology +17

Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy

Tetsutaro Hayashi, Kilian M. Gust, Alexander W. Wyatt et al. · Clinical Cancer Research · 2016 · 88 citations

Medicine, Molecular Genetics, Oncology +17

Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer

Tetsutaro Hayashi, Roland Seiler, Htoo Zarni Oo et al. · The Journal of Urology · 2015 · 84 citations

Medicine, Oncology, Pharmacology +17

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab

Takashi Kobayashi, Katsuhiro Ito, Takahiro Kojima et al. · Cancer Science · 2020 · 73 citations · Full text

Medicine, Biostatistics, Oncology +14